Spyre Therapeutics (SYRE) CFO Scott Burrows Sells 15,000 Shares

Chief Financial Officer Scott Burrows Exercises Options

Scott Burrows, the Chief Financial Officer of Spyre Therapeutics, Inc. (SYRE), acquired 15,000 shares of the company on June 25, 2026. This transaction was an exercise of stock options at a price of $14.50 per share, representing a total value of $217,500. Unlike some other recent trades at the firm, this specific move by the CFO was not conducted under a Rule 10b5-1 trading plan.

This activity is part of a broader pattern of insider movement at the Waltham-based biotech firm. Just days earlier, on June 22, 2026, insider Henderson Michael Thomas sold 20,000 shares at $100.00 each through a pre-arranged trading plan. Additionally, Fairmount Funds Management LLC has been active, purchasing 666,680 shares on June 23, 2026, while also selling a large block of 4,684,781 shares that same day at an average price of $85.31.

Spyre Therapeutics Stock Performance

Shares of Spyre Therapeutics were trading at $87.89 on Saturday. The stock has shown significant momentum over the past year, rising from a 52-week low of $15.11. While it is currently trading below its 50-day moving average of $97.83, it remains comfortably higher than its long-term 200-day moving average of $65.16. The company carries a market capitalization of approximately $8.11 billion.

From a financial health perspective, the company maintains a strong liquidity position. Its current ratio, which measures a company's ability to pay short-term obligations, stands at 18.53. However, as a clinical-stage biotechnology firm, Spyre is not yet profitable, reporting a recent earnings per share (EPS) loss of $1.92. This is common for companies in the drug development phase that are spending heavily on research.

Analysts Set New Price Targets

Wall Street firms have been increasingly vocal about Spyre's potential. On October 12, 2026, UBS initiated coverage on the stock with a Buy rating and a $120.00 price target. This followed a similar move by JP Morgan on October 1, 2026, which started the stock with an Overweight rating and a $110.00 target.

Other analysts have recently adjusted their expectations. Deutsche Bank maintained a Buy rating on August 26, 2026, though it lowered its price target to $127.00 from a previous $135.00. Similarly, Wedbush reiterated its Outperform rating in September with a $123.00 target. Across 13 analyst opinions, the stock currently holds a strong buy consensus with an average target price of $120.08.

Focused on Inflammatory Diseases

Spyre Therapeutics focuses on creating new treatments for people suffering from inflammatory bowel disease (IBD) and rheumatic conditions. Its lead programs, such as SPY001 and SPY003, are in phase-2 clinical trials. The company aims to improve patient care by developing humanized monoclonal antibodies that target specific proteins involved in inflammation. Formerly known as Aeglea BioTherapeutics, the company rebranded in late 2023 to focus entirely on its IBD pipeline.

What's Ahead for Spyre Therapeutics, Inc.

Investors monitoring the biotech sector will likely look to the company's next earnings update, scheduled for November 3, 2026. While insider transactions like those from the CFO provide a look at executive sentiment, they are often part of long-term compensation strategies. Future clinical trial results for the SPY001 and SPY002 programs will likely be the primary drivers for the stock in the coming months.